A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock

Medical Hypotheses

Volumn 67, Issue 1, 2006, Pages 124-142

  Wheatley, Carmen ^a  

^a Orthomolecular Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BETA INTERFERON; COBALAMIN; COBALAMIN DERIVATIVE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; GLUTATHIONE; HYDROXOCOBALAMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; NITRIC OXIDE; NITROSYLCOBALAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; UNCLASSIFIED DRUG;

ARTICLE; BACTERIOSTASIS; BRADYCARDIA; CELL RESPIRATION; CYANIDE POISONING; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; GENE EXPRESSION; HEREDITY; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE ORGAN FAILURE; NONHUMAN; OUTCOME ASSESSMENT; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; STATISTICAL SIGNIFICANCE; STOICHIOMETRY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACETYLCHOLINE; GLUTATHIONE; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SEPSIS; SHOCK, SEPTIC; SHOCK, TRAUMATIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VITAMIN B 12;

ANAGALLIS ARVENSIS; ANIMALIA;

EID: 33646475421     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.01.036     Document Type: Article

References (137)

1. Friedman G., Silva E., Vincent J.L., et al. Has the mortality of septic shock changed with time?. Crit Care Med 26 (1998) 2078-2086
2. Padkin A., Goldfrad C., Brady A.R., et al. Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales and Northern Ireland. Crit Care Med 31 (2003) 2332-2338
3. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. New Engl J Med 348 (2003) 1546-1554
4. Ball J. What are the challenges of translating positive trial results in severe sepsis into clinical practice? A media roundtable debate, 18 March 2002, Brussels. Crit Care 6 (2002) 271-274
5. Lin B., Williams-Skipp C., Tao Y., et al. NFκB functions as both a pro-apoptotic and anti-apoptotic regulatory factor within a single cell type. Cell Death Differ 6 (1999) 570-582
6. D'Acquisto F., May M.J., and Ghosh S. Inhibition of nuclear factor kappa B (NFκB): an emerging theme in anti-inflammatory therapies. Molecular Interventions 2 (2002) 22-35
7. Andersson U., Wang H., Palmblada K., et al. High mobility group 1 protein (hmg-1) stimulates pro-inflammatory cytokines in human monocytes. J Exp Med 192 (2000) 565-570
8. Blalock J.E. Harnessing a neural-immune circuit to control inflammation and shock. J Exp Med 195 (2002) F25-F28
9. Endres S., Ghorbani R., Kelley V.E., et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. New Engl J Med 320 (1989) 265-271
10. Serhan C.N., Clish C.B., Brannon J., et al. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from ω-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 Oct (2000) 1197-1204
11. Borovikova L.V., Lvanona S., Zhang M., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000) 458-462
12. Lawrence T., Gilroy D.W., Colville-Nash P.R., and Willoughby D.A. Possible new role for NFκB in the resolution of inflammation. Nature Med 7 12 (2001) 1291-1297
13. Evans T.J., and Cohen J. Mediators: nitric oxide and other toxic oxygen species. In: Rietschel E.T., and Wagner H. (Eds). Pathology of septic shock (1996), Springer-Verlag, Berlin, Heidelberg 189-208
14. Llesuy S., Evelson P., Gonzalez-Flecha B., et al. Oxidative stress in muscle and liver of rats with septic syndrome. Free Radic Biol Med 16 (1994) 445-451
15. Poderoso J.J., Carreras M.C., Lisdero C., et al. Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch Biochem Biophys 328 1 (1996) 85-92
16. Riedemann N.C., Guo R.-F., and Ward P.A. Novel strategies for the treatment of sepsis. Nature Med 9 5 (2003) 517-524
17. Wright C.E., Rees D., and Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 26 (1992) 48-57
18. Reinhart K., and Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 29 (2001) S121-S125
19. Greenberg S.S., Zie J., Zatarain J.M., et al. Hydroxocobalamin (vitamin B12) prevents and reverses endotoxin-induced hypertension and mortality in rodents: role of nitric oxide. J Pharm Exp Therap 273 (1995) 257-265
20. Traina V. Vitamin B12 as an anti-anaphylactic. Nature 166 (1950) 78-79
21. Posner M.A., Rodkey F.L., and Tobey R.E. Nitroprusside-induced cyanide poisoning: antidotal effect of hydroxocobalamin. Anaesthes 44 (1976) 330-335
22. Lazarev N.V., and Vishniakov S.M. Problem of increasing resistance of the organism to operative trauma by medical means. Vestn Khir 79 11 (1957) 19-23 [In Russian]
23. Badyuzin I.S. The anti-shock activity of large doses of cyanocobalamin. Byull Eksp Biol Med 60 (1965) 62-64
24. Mitrofanov VG. The pathogenesis of traumatic shock and its complication with radiation sickness. Diss dokt, Leningrad; 1959 [In Russian].
25. Howard J.M., and deBakey M.E. The treatment of hemorrhagic shock with cortisone and vitamin B12. Surgery 30 (1951) 161-165
26. Yacoub M., Faure H., Morena M., et al. L'intoxication cyanhydrique aiguë. Données actuelles sur le métabolisme du cyanure et le traitement par hydroxocobalamine. J Europ de Toxicol 7 (1974) 22-29 [In French]
27. Motin J., Bouletrean P., and Rouzious J.M. Intoxication cyanhydrique grave traitée avec succès par hydroxocobalamine. J Med de Strasbourg I (1970) 717-722 [In French]
28. Tassan H., Joyon D., Richard T., et al. Intoxication au cyanure de potassium traitée par l'hydroxocobalamine. Ann Fr Anesth Reanim 9 (1990) 383-385 [In French]
29. Brouard A., Blaisot B., and Bismuth C. Hydroxocobalamine in cyanide poisoning. J de Toxicol Clin et Exp 7 (1987) 155-168
30. Forsyth J.C., Mueller P.D., Becker C.E., et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. Clin Toxicol 31 (1993) 277-294
31. Riou B., Gérard J.L., Drieu la Rochelle C., et al. Hemodynamic effects of hydroxocobalamin in conscious dogs. Anaesthes 74 (1991) 552-558
32. Hall A.H., and Rumack B.H. Hydroxocobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 5 (1987) 115-121
33. Markle H.V. Cobalamin. Crit Rev Clin Lab Sci 33 (1996) 247-256
34. Nexø E.,. Cobalamin binding proteins. In: Kräutler B., Arigoni D., and Golding B.T. (Eds). Vitamin B12 and B12 proteins (1998), Wiley, La Jolla 461-475
35. Beck W.S. Biological and medical aspects of vitamin B12. In: Dolphin D. (Ed). B12, biochemistry and medicine (1982), Wiley, New York 1-30
36. Seetharam B. Receptor-mediated endocytosis of cobalamin (vitamin B12). Annu Rev Nutr 19 (1999) 173-195
37. Ostray F., and Gams R.A. Cellular fluxes of vitamin B12. Blood 50 (1997) 877-888
38. Moestrup SK. Cellular surface receptors important for vitamin B12 nutrition. Kräutler B, et al. Op cit. p. 477-89.
39. Carmel R. The distribution of endogenous cobalamin among cobalamin-binding proteins in the blood in normal and abnormal states. Am J Clin Nutr 41 (1985) 713-719
40. Zittoun J., Marquet J., and Zittoun R. The intracellular content of the three transcobalamins at various stages of normal and leukaemic myeloid cell development. Brit J Haematol 31 (1975) 299-310
41. Poston J.M. β-leucine and the β-keto pathway of leucine metabolism. Adv Enzymol 58 (1986) 173-189
42. Stabler S.P., Lindenbaum J., and Allen R.H. Failure to detect b-leucine in human blood or leucine 2, 3-aminomutase in rat liver using capillary gas chromatography - mass spectrometry. J Biol Chem 263 12 (1988) 5581-5588
43. Olesen H., Andersen M.P., and Amris A. Serum vitamin B12 binding capacity in patients with anaemia. Scand J Haematol 5 (1968) 235-240
44. Seetharam B., and Li N. Transcobalamin II and its cell surface receptors. Vitam Horm 59 (2000) 337-366
45. Ghosh K., Mohanty D., Rana K.S., et al. Plasma transcobalamins in haematological disorders. Folia Haematol Int Mag Klin Morphol Blutforsch 113 (1986) 766-775
46. Christensen P.A., Brynskov J., Gimsing P., and Petersen J. Vitamin B12 binding proteins (transcobalamin and haptocorrin) in serum and synovial fluid of patients with rheumatoid arthritis and traumatic synovitis. Scand J Rheumatol 12 (1983) 268-272
47. Lasser U., Kierat L., Grob P., et al. Transcobalamin II, a serum protein reflecting autoimmune disease activity, its plasma dynamics, and the relationship to established serum parameters in systemic lupus erythematosus. Clin Immunol Immunopathol 36 (1985) 345-357
48. Rachmilewitz D., Ligumsky M., Rachmilewitz B., et al. Transcobalamin II level in peripheral blood monocytes - a biochemical marker in inflammatory diseases of the bowel. Gastroenterology 78 (1980) 43-46
49. Nexø E, Olesen H. Intrinsic factor, transcobalamin, and haptocorrin. In: Dolphin D, editor. p. 57-85; and references therein.
50. Macdonald C., Bessent R., and Adams J. Transcobalamin-binding capacities in vitamin B12-related diseases. Am J Clin Pathol 75 (1981) 677-683
51. Herbert V. B12 deficiency in AIDS. JAMA 260 (1988) 2837
52. Carmel R., and Eisenberg L. Serum B12 and transcobalamin abnormalities in people with cancer. Cancer 40 (1977) 1348-1353
53. Lindenbaum J., Rosenberg I.H., Wilson P.W., et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 60 (1994) 2-11
54. Baeuerle P., and Baltimore D. Meeting review. NFκB 10 years after. Cell 87 (1996) 13-20
55. Baeuerle P., and Henkel T. Function and activation of NFκB in the immune system. Annu Rev Immunol 12 (1994) 141-179
56. Bonizzi G., and Karin M. The two NFκB activation pathways and their role in innate and adaptive immunity. Trends in Immunol 25 (2004) 280-288
57. Schreck R., Rieber P., and Baeuerle P. Reactive oxygen species as apparently widely used messengers in the activation of the NFκB transcription factor and HIV-1. EMBO 10 (1991) 2247-2258
58. O'Neill L.A.J. Immunity's early warning system. Scientific American January (2005) 24-31
59. Peracchi M., Bamonti Catena F., Pomati M., et al. Human cobalamin deficiency: alterations in serum tumour necrosis factor-α and epidermal growth factor. Eur J Haematol 67 (2001) 123-127
60. Steadman R., Petersen M.M., Williams N., et al. The selective augmentation by recombinant human tumour necrosis factor-α of neutrophil responses to pathogenic Eschericia coli. Immunology 70 (1990) 133-135
61. Krehan A., Ansuini H., Böcher O., et al. Transcription factors, Ets-1, NFκB, and Sp1 are major determinants of the promoter activity of the human protein kinase CK2α gene. J Biol Chem 275 (2000) 18327-18336
62. Johnston J., Yang-feng T., and Berliner N. Genomic structure and mapping of the chromosomal gene for transcobalamin I (TCNI): comparison to human intrinsic factor. Genomics 12 (1992) 459-464
63. Wang S., Wang W., Wesley R.A., and Danner R.L. A Sp1 binding site of the TNFα promoter functions as a nitric oxide response element. J Biol Chem 274 (1999) 33190-33193
64. Pardali K., Kurisaki A., and Moren A. Role of Smad proteins and transcription factor Sp1 in p21 (Waf1/Cip1) regulation of TGFβ. J Biol Chem 275 (2000) 29244-29256
65. Merchant J.L., Shiotani A., Mortensen E.R., et al. Epidermal growth factor stimulation of the human gastrin promoter requires Sp1. J Biol Chem 270 (1995) 6314-6319
66. Moore K. The scientific basis of wound healing. Adv Tiss Bank 5 (2001) 379-397
67. Yamashiki M., Nishimura A., and Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 37 (1992) 173-182
68. Cytokines as mediators in the pathogenesis of septic shock. In: Rietschel ET, Wagner H, editors. p. 133-65.
69. Meydani S.N., and Dinarello C.A. Influence of dietary fatty acids on cytokine production and its clinical implications. Nutr Clin Pract 8 (1993) 65-72
70. Bauer J.A., Morrison B.H., Grane R.W., et al. Effects of interferon β on transcobalamin II - receptor expression and anti-tumour activity of nitrosylcobalamin. J Nat Canc Inst 94 (2002) 1010-1019
71. Chawla-Sarkar M., Bauer J.A., Lupica J.A., et al. Suppression of NFκB survival signalling by nitrosylcobalamin sensitizes neoplasms to the anti-tumour effects of Apo2L/TRAIL. J Biol Chem 278 (2003) 39461-39469
72. Pezacka E., Green R., and Jacobsen D.W. GSHCbl as an intermediate in the formation of cobalamin coenzymes. Biochem Biophys Res Commun 169 (1990) 443-450
73. Scheuring E.M., Sagi I., and Chance M.R. Sulfur-containing cobalamins: X-ray absorption spectroscopic characterization. Biochemistry 33 (1994) 6310-6315
74. Suto R.K., Brasch N.E., Anderson O.P., and Finke R.G. Synthesis, characterisation, solution stability, and X-ray crystal structure of the thiolatocobalamin-γ-glutamylcysteinyl-cobalamin, a dipeptide analogue of glutathionylcobalamin: insights into the enhanced Co-S bond stability of the natural product glutathionylcobalamin. Inorg Chem 40 (2001) 2686-2692
75. Kruszyna H., Magyar J.S., Rochelle L.G., et al. Spectroscopic studies of nitric oxide (NO) interactions with cobalamins: reaction of NO with superoxocobalamin (III) likely accounts for cobalamin reversal of the biological effects of NO. J Pharmacol Exp Therap 285 (1998) 665-671
76. Lane P., and Gross S.S. Nitric oxide: promiscuous and duplicitous. Sci Med 8 (2002) 96-107
77. Sellak H., Yang X., Cao X., et al. Sp1 transcription as a molecular target for NO - and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase Iα expression in vascular smooth muscle cells. Circ Res 90 (2002) 405-412
78. Rajanayagam M.A.S., Li C.G., and Rand M.J. Differential effects of hydroxocobalamin on NO-mediated relaxations in rat aorta and anococcygeus muscle. Br J Pharmacol 108 (1993) 3-5
79. Brouwer M., Chamulitrat W., Ferruzi G., et al. Nitric oxide interactions with cobalamins: biochemical and functional consequences. Blood 88 (1996) 1857-1864
80. Ling C.T., and Chow B.F. Effect of vitamin B12 on the levels of soluble sulfhydryl compounds in blood. J Biol Chem 202 (1953) 445-456
81. Register U.D. The effect of vitamin B12 on liver and blood non-protein sulfhydryl compounds. J Biol Chem 206 (1954) 705-709
82. Hondorp E.R., and Mathews R.G. Oxidative stress inactivates cobalamin-dependent methionine synthase (MetE) in Eschericia coli. PLOS-Biol 2 (2004) e336
83. Dubnoff J.W., and Bartron E. The effect of B12 on enzyme activity in E. coli mutant 113-3. Arch Biochem Biophys 61 (1956) 99-110
84. Will J.J., Mueller J.F., Glazer H.S., et al. J Lab Clin Med 42 (1953) 967
85. c) studies, plus the possibility that coenzyme B12-dependent enzymes function as 'ultimate radical cages' and 'ultimate radical traps'. Inorg Chem 32 (1993) 4414-4421
86. Clementi E., Brown G.C., Feelisch M., and Moncada S. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 95 (1998) 7631-7636
87. Bolanos J.P., Heales S.J., Peuchen S., et al. Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Rad Biol Med 21 (1996) 995-1001
88. Poderoso J.J., Boveris A., Jorge M.A., et al. Funcion mitocondrial en el shock septico. Medicina 38 (1978) 371-377 [In Spanish]
89. Brealey D., Brand M., Hargreaves I., et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360 (2002) 219-223
90. Thijs LG, Groeneveld ABJ, Hack CE. Multiple organ failure in shock. In: Rietschel ET, Wagner H, editors. p. 209-37.
91. Baker H., Leevy C.B., De Angelis B., et al. Cobalamin (vitamin B12) and holotranscobalamin changes in plasma and liver tissue in alcoholics with liver disease. J Am Coll Nutr 17 (1998) 235-238
92. Bolton C.F., Young G.B., and Zochodne D.W. Neurological changes during severe sepsis. In: Burchardii H., Dobb G., Biou J., and Dellinger R.F. (Eds). Current topics in intensive care vol. I (1994), Saunders, London: W.B. 180-218
93. Wang H.X., Wahlin A., and Basun H. Vitamin B12 and folate in relation to the development of Alzheimer's disease. Neurology 56 (2001) 118-194
94. Karnaze D.S., and Carmel R. Low serum cobalamin levels in primary degenerative dementia. Arch Intern Med 147 (1987) 429-431
95. Heales S.J., Bolanos J.P., and Clark J.B. Glutathione depletion is accompanied by increased neuronal nitric oxide synthase activity. Neurochem Res 21 (1996) 35-39
96. Beard M.E.J., Hatipov C.S., and Hamer J.W. Acute marrow folate deficiency during intensive care. BMJ 1 (1978) 624-625
97. Ibbotson R.M., Colvin B.T., and Colvin M.P. Folic acid deficiency during intensive therapy. BMJ 4 (1975) 145
98. Nunn J.F. Clinical aspects of the interaction between nitrous oxide and vitamin B12. Br J Anaesth 59 (1987) 3-13
99. Zittoun J., and Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. Sem Hemat 36 (1999) 35-46
100. Metz J., Kelly A., Chapin Swett V., et al. Deranged DNA synthesis by bone marrow from vitamin B12 deficient humans. Br J Haematol 14 (1968) 575-591
101. Adeghate E., and Parvez S.H. Nitric oxide and neuronal and pancreatic beta cell death. Toxicology 153 (2000) 143-156
102. Van den Berghe G., Wouters P.J., Bouillon R., et al. Outcome benefits of intensive insulin therapy in the critically ill: insulin dose versus glycaemic control. Crit Care Med 31 (2003) 359-366
103. Moestrup S.K., Birn H., Fischer P.B., et al. Megalin-mediated endocytosis of transcobalamin-vitamin B12 complexes suggests a role of the receptor in vitamin B12 homeostasis. Proc Natl Acad Sci USA 93 (1996) 8612-8617
104. Cohen J. The immunopathogenesis of sepsis. Nature (insight: Inflammation) 420 (2002) 885-889
105. Smith T.E. Molecular cell biology. In: Devlin T.M. (Ed). Textbook of biochemistry with clinical correlations (1997), Wiley, New York 960-976
106. Watson J.D., Hopkins H., Roberts J.W., Argetsinger Steitz J., and Weiner A.M. The control of cell proliferation. In: Watson J.D. (Ed). Molecular biology of the gene (1988), Benjamin/Cummings, California 962-1005
107. Arkanac B.M., Foster L.C., Sibinaga N.E.S., et al. Vascular endothelial growth factor induces heparin binding epidermal growth factor-like growth factor in vascular endothelial cells. J Biol Chem 273 (1998) 4400-4405
108. Masuda Y., Kokubu T., Yamashita M., et al. Egg phosphatidylcholine combined with vitamin B12 improved memory impairment following lesioning of nucleus basilis in rats. Life Sci 62 (1998) 813-822
109. Hung M.C., Shibasaki K., Nishizono S., et al. Ibotenic acid-induced lesions of the medial septum increase hippocampal membrane associated protein kinase C activity and reduce acetylcholine synthesis: prevention by a phosphatidylcholine/vitamin B12 diet. J Nutr Biochem 11 (2000) 159-164
110. Tracey K.Y. The inflammatory reflex. Nature Inflammation 420 (2002) 853-859
111. Guarini S., Altavilla D., Cainazzo M.M., et al. Efferent vagal fibre stimulation blunts nuclear factor-κB activation and protects against hypovolemic hemorrhagic shock. Circulation 107 (2003) 1189-1194
112. Wang H., Liao H., Ochani M., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Med 10 (2004) 1216-1221
113. Wang H., Bloom O., Zhang M., et al. Hmg-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
114. Czura C.J., Yang H., Amella C.A., et al. HMGB1 in the immunology of sepsis (not shock) and arthritis. Adv Immunol 84 (2004) 181-200
115. Gilbert H.S. Proposal of a possible function for granulocyte vitamin B12 binding proteins in host defense against bacteria. Blood 44 (1974) 926
116. Khanna-Gupta A., Zibello T., Simkevich C., et al. Sp1 and C/EBP are necessary to activate the lactoferrin gene promoter during myeloid differentiation. Blood 95 (2000) 3734-3741
117. Adkins Y., and Lannerdal B. Potential host-defense role of a human milk vitamin B12-binding protein, haptocorrin, in the gastrointestinal tract of breastfed infants as assessed with porcine haptocorrin in vitro. Am J Clin Nutr 77 (2003) 1234-1240
118. Seger R., Wildfeuer A., Frater-Schroder M., et al. Granulozytendysfunktion bei Transcobalamin-II-Mangel. Schweiz Med Wochenschr 109 (1979) 1375-1376 [In German]
119. Inglis T.J.J. The challenge of increasing antibiotic resistance in intensive care. In: Burchardii H., Dobbs G.J., Bion J., and Dellinger R.P. (Eds). Current topics in intensive care vol. 4 (1997), W.B. Saunders, London 164-181
120. Smith R.J., Speziale S.C., and Bowman B.J. Properties of interleukin-1 as a complete secretagogue for human neutrophils. Biochem Biophys Res Commun 130 (1985) 1233-1240
121. Clark R.A., and Borregaard N. Neutrophils autoinactivate secretory products by myeloperoxidase-catalyzed oxidation. Blood 65 (1985) 375-381
122. Pajkrt D., and van Deventer S.J.H. The cellular response in sepsis. Curr Top Microbiol Immunol 216 (1996) 119-132
123. Hucke C., Mackenzie C.R., Adjogble K.D., et al. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. Infect Immun 72 (2004) 2723-2730
124. Weinberg J., Sauls D.L., Misukonis M.A., and Shugars D.C. Inhibition of productive human immunodeficiency virus-1 infection by cobalamins. Blood 86 (1995) 1281-1287
125. Remacha A.F., and Cadafalch J. Cobalamin deficiency in patients infected with the human immunodeficiency virus. Sem Hematol 36 (1999) 75-87
126. Sears B. Essential fatty acids, eicosanoids, and cancer. In: Quillin P., and Williams R.M. (Eds). Adjuvant nutrition in cancer treatment (1993), Cancer Treatment Research Foundation, USA 267-282
127. Kopp E., and Ghosh S. Inhibition of NFκB by sodium salicylate and aspirin. Science 265 (1994) 956-959
128. Prescott S.M., and Stenson W.F. Fish oil fix. Nature Med 11 (2005) 596-597
129. Hodgkin D.C., Kamper J., Mackay M., et al. Structure of vitamin B12. Nature 178 (1956) 64-66
130. Fenton W.A., and Rosenberg L.E. Inherited disorders of cobalamin transport and metabolism. In: Scriver C.R., Badet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited disease (1995), McGraw-Hill, New York 3129-3150
131. Bodian M. Neuroblastoma. Pediatr Clin North Am 6 (1959) 449-472
132. Bernik T.R., Friedman S.G., and Ochani M. Pharmacological stimulation of the cholinergic anti-inflammatory pathway. J Exp Med 6 (2002) 781-788
133. Miller J.W., Marisa I., and Ramos M.G. TCII 775G > C polymorphism and indices of vitamin B12 status in healthy older adults. Blood 100 (2002) 718-720
134. Nakanishi C., and Toi M. Nuclear factor-κB inhibitors as sensitizers to anti-cancer drugs. Nature Rev Cancer 5 (2005) 297-309
135. Pikarsky E., Porat R.M., Stein I., et al. NFκB functions as a tumour promoter in inflammation-associated cancer. Nature 431 7007 (2004) 405-406
136. Kraft U. Mending the spinal cord. Scientific American Mind 16 3 (2005) 68-73
137. Eschenmoser A. Foreword, iv-vi. In: Kräutler B, editor. op cit.